Recombinant Human TNFSF12 Protein (Active) is a Human Fragment protein, in the 93 to 249 aa range, expressed in HEK 293, with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE.
>=95% SDS-PAGE
<= 0.005 EU/µg
HEK 293 cells
Tag free
SDS-PAGE
Yes
R S A P K G R K T R A R R A I A A H Y E V H P R P G Q D G A Q A G V D G T V S G W E E A R I N S S S P L R Y N R Q I G E F I V T R A G L Y Y L Y C Q V H F D E G K A V Y L K L D L L V D G V L A L R C L E E F S A T A A S S L G P Q L R L C Q V S G L L A L R P G S S L R I R T L P W A H L K A A P F L T Y F G L F Q V H
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion.
APO3L, DR3LG, UNQ181/PRO207, TNFSF12, Tumor necrosis factor ligand superfamily member 12, APO3 ligand, TNF-related weak inducer of apoptosis, TWEAK
Recombinant Human TNFSF12 Protein (Active) is a Human Fragment protein, in the 93 to 249 aa range, expressed in HEK 293, with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE.
>=95% SDS-PAGE
<= 0.005 EU/µg
HEK 293 cells
Tag free
SDS-PAGE
Yes
Fully biologically active determined by its ability to dose dependently proliferate human umbilical vein endothelial cells (HUVECs). ED50 is ≤16.7 ng/ml, corresponding to a specific activity of 6.1x105 units/mg.
Yes
Human
Reconstitute in PBS
pH: 7.4
Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.248% Potassium phosphate monobasic
R S A P K G R K T R A R R A I A A H Y E V H P R P G Q D G A Q A G V D G T V S G W E E A R I N S S S P L R Y N R Q I G E F I V T R A G L Y Y L Y C Q V H F D E G K A V Y L K L D L L V D G V L A L R C L E E F S A T A A S S L G P Q L R L C Q V S G L L A L R P G S S L R I R T L P W A H L K A A P F L T Y F G L F Q V H
Fragment
17.41 kDa
93 to 249
Recombinant
Lyophilized
Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion.
Belongs to the tumor necrosis factor family.
The soluble form derives from the membrane form by proteolytic processing.
Ambient - Can Ship with Ice
Ambient
Ambient
This product is an active protein and may elicit a biological response in vivo, handle with caution.
This supplementary information is collated from multiple sources and compiled automatically.
The TNF-like weak inducer of apoptosis (TWEAK) also known as CD255 is a cytokine involved in a variety of cellular processes. This protein has an approximate mass of 24 kDa. TWEAK is expressed in many tissues including the heart brain and spleen. It functions by binding to the fibroblast growth factor-inducible 14 (Fn14) receptor leading to the activation of downstream signaling pathways. TWEAK's role as a ligand places it in the tumor necrosis factor (TNF) superfamily highlighting its involvement in cell death and inflammation signaling.
TWEAK modulates processes like cell proliferation differentiation and apoptosis. This cytokine affects the immune response and tissue regeneration becoming significant in processes that require tissue remodeling. While acting independently TWEAK does not form part of a larger protein complex. Instead it signals mainly through its exclusive receptor Fn14 on responsive cells triggering cellular responses that influence its biological activities.
TWEAK plays an important role in the NF-kB and MAPK signaling pathways. These pathways are important for immune response regulation and cell survival. In these pathways TWEAK closely interacts with TNF receptor-associated factors (TRAFs) which facilitate TWEAK signaling. The connections to pathways involving inflammatory response highlight its significance in maintaining homeostasis within the cellular environment.
TWEAK's activity links to conditions like cancer and rheumatoid arthritis. In cancer excessive TWEAK signaling can contribute to tumor growth and metastasis through its pro-inflammatory and pro-angiogenic effects. In rheumatoid arthritis TWEAK expression relates to joint inflammation and tissue damage where it interacts with proteins like IL-6 and TNF-alpha. These interactions suggest potential therapeutic targets by modulating TWEAK or its signaling partners to treat these diseases.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
SDS-PAGE analysis of ab283416.
Fully biologically active determined by its ability to dose dependently proliferate human umbilical vein endothelial cells (HUVECs). ED50 is ≤16.7 ng/ml, corresponding to a specific activity of 6.1x105 units/mg.
Cell based assay testing is performed on the first lot of protein only and is provided as a reference for protein activity; subsequent lots of protein must pass all biophysical quality control parameters that meet the same parameters as the first lot.
Lot GR3398997-2
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com